{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:53:44Z","timestamp":1788486824416,"version":"build-2803163510"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum des Saarlandes und Medizinische Fakult\u00e4t der Universit\u00e4t des Saarlandes"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Advanced Parkinson\u2019s disease (APD) represents a late stage of Parkinson\u2019s disease and is characterized by complex motor and non-motor symptoms that are less responsive to oral dopaminergic therapies. While APD has a relevant impact on patients\u2019 quality of life and requires intensified treatment, consistent diagnostic criteria have only recently been proposed. The precise pathophysiology underlying the symptoms of APD remains poorly understood, making early prognostication and intervention difficult. Neuroimaging has emerged as a promising tool for elucidating the mechanisms driving APD, identifying biomarkers for disease staging, and predicting therapeutic response. Techniques such as molecular imaging and magnetic resonance imaging provide insight into molecular and structural changes associated with the progression of PD, including protein aggregation, neuroinflammation, and regional neurodegeneration. While positron emission tomography imaging of alpha-synuclein and other pathologies offers avenues for staging and differential diagnosis, advanced magnetic resonance imaging approaches have the potential for capturing subtle microstructural changes i.e. through neuromelanin-sensitive or diffusion-weighted imaging. However, the majority of imaging studies has focused on early Parkinson\u2019s disease, leaving their applicability to APD uncertain. Future research should prioritize the validation of neuroimaging findings in well-defined APD cohorts and extend their use to predict clinical milestones such as motor fluctuations, dyskinesia, and cognitive decline. These efforts are essential to advance personalized therapeutic strategies and bridge the gap between research and clinical management of APD.<\/jats:p>","DOI":"10.1007\/s00702-025-02942-y","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T09:13:35Z","timestamp":1747041215000},"page":"1655-1664","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Neuroimaging in advanced Parkinson\u2019s disease: insights into pathophysiology, biomarkers, and personalized therapies"],"prefix":"10.1007","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3833-9822","authenticated-orcid":false,"given":"Nils","family":"Schr\u00f6ter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergiu","family":"Groppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Rijntjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Gonzalez-Escamilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst","family":"Urbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang H.","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Rau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"key":"2942_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-021-00280-3","volume":"7","author":"D Aarsland","year":"2021","unstructured":"Aarsland D, Batzu L, Halliday GM et al (2021) Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers 7:1\u201321. https:\/\/doi.org\/10.1038\/s41572-021-00280-3","journal-title":"Nat Rev Dis Primers"},{"key":"2942_CR2","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1002\/mds.28617","volume":"36","author":"KB Andersen","year":"2021","unstructured":"Andersen KB, Hansen AK, Damholdt MF et al (2021) Reduced synaptic density in patients with lewy body dementia: an [C]UCB-J PET imaging study. Mov Disord 36:2057\u20132065. https:\/\/doi.org\/10.1002\/mds.28617","journal-title":"Mov Disord"},{"key":"2942_CR3","doi-asserted-by":"publisher","first-page":"e222","DOI":"10.1016\/S2589-7500(19)30105-0","volume":"1","author":"DB Archer","year":"2019","unstructured":"Archer DB, Bricker JT, Chu WT et al (2019) Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study. Lancet Digit Health 1:e222\u2013e231. https:\/\/doi.org\/10.1016\/S2589-7500(19)30105-0","journal-title":"Lancet Digit Health"},{"key":"2942_CR4","doi-asserted-by":"publisher","first-page":"369541","DOI":"10.3389\/fneur.2019.00378","volume":"10","author":"A Ashraf-Ganjouei","year":"2019","unstructured":"Ashraf-Ganjouei A, Kheiri G, Masoudi M et al (2019) White matter tract alterations in Drug-Na\u00efve Parkinson\u2019s disease patients with excessive daytime sleepiness. Front Neurol 10:369541. https:\/\/doi.org\/10.3389\/fneur.2019.00378","journal-title":"Front Neurol"},{"key":"2942_CR5","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1001\/archneur.60.12.1745","volume":"60","author":"NI Bohnen","year":"2003","unstructured":"Bohnen NI, Kaufer DI, Ivanco LS et al (2003) Cortical cholinergic function is more severely affected in parkinsonian dementia than in alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 60:1745\u20131748. https:\/\/doi.org\/10.1001\/archneur.60.12.1745","journal-title":"Arch Neurol"},{"key":"2942_CR6","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S1474-4422(21)00377-X","volume":"21","author":"NI Bohnen","year":"2022","unstructured":"Bohnen NI, Yarnall AJ, Weil RS et al (2022) Cholinergic system changes in Parkinson\u2019s disease: emerging therapeutic approaches. Lancet Neurol 21:381\u2013392. https:\/\/doi.org\/10.1016\/S1474-4422(21)00377-X","journal-title":"Lancet Neurol"},{"key":"2942_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaneurol.2020.2526","volume":"77","author":"M Brendel","year":"2020","unstructured":"Brendel M, Barthel H, van Eimeren T et al (2020) Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy. JAMA Neurol 77:1\u201313. https:\/\/doi.org\/10.1001\/jamaneurol.2020.2526","journal-title":"JAMA Neurol"},{"key":"2942_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/ana.27005","volume":"96","author":"J Brumberg","year":"2024","unstructured":"Brumberg J, Blazhenets G, B\u00fchler S et al (2024) Cerebral glucose metabolism is a valuable predictor of survival in patients with lewy body diseases. Ann Neurol 96:539\u2013550. https:\/\/doi.org\/10.1002\/ana.27005","journal-title":"Ann Neurol"},{"key":"2942_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-024-00688-0","volume":"10","author":"X Cao","year":"2024","unstructured":"Cao X, Gan C, Zhang H et al (2024) Altered perivascular spaces in subcortical white matter in Parkinson\u2019s disease patients with levodopa-induced dyskinesia. Npj Parkinsons Dis 10:1\u20139. https:\/\/doi.org\/10.1038\/s41531-024-00688-0","journal-title":"Npj Parkinsons Dis"},{"key":"2942_CR10","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/ana.25994","volume":"89","author":"F Cavallieri","year":"2021","unstructured":"Cavallieri F, Fraix V, Bove F et al (2021) Predictors of Long-Term outcome of subthalamic stimulation in Parkinson disease. Ann Neurol 89:587\u2013597. https:\/\/doi.org\/10.1002\/ana.25994","journal-title":"Ann Neurol"},{"key":"2942_CR11","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3109\/00207454.2015.1023437","volume":"126","author":"M Chondrogiorgi","year":"2016","unstructured":"Chondrogiorgi M, Tzarouchi LC, Zikou AK et al (2016) Multimodal imaging evaluation of excessive daytime sleepiness in Parkinson\u2019s disease. Int J Neurosci 126:422\u2013428. https:\/\/doi.org\/10.3109\/00207454.2015.1023437","journal-title":"Int J Neurosci"},{"key":"2942_CR12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrneurol.2012.126","volume":"8","author":"M Coelho","year":"2012","unstructured":"Coelho M, Ferreira JJ (2012) Late-stage Parkinson disease. Nat Rev Neurol 8:435\u2013442. https:\/\/doi.org\/10.1038\/nrneurol.2012.126","journal-title":"Nat Rev Neurol"},{"key":"2942_CR13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/ana.65.abs","volume":"49","author":"R de la Fuente-Fern\u00e1ndez","year":"2001","unstructured":"de la Fuente-Fern\u00e1ndez R, Lu JQ, Sossi V et al (2001) Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson\u2019s disease: PET evidence of increased dopamine turnover. Ann Neurol 49:298\u2013303. https:\/\/doi.org\/10.1002\/ana.65.abs","journal-title":"Ann Neurol"},{"key":"2942_CR14","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Sherer T, Okun MS, Bloem BR (2018) The emerging evidence of the Parkinson pandemic. J Parkinsons Dis 8:S3\u2013S8. https:\/\/doi.org\/10.3233\/JPD-181474","journal-title":"J Parkinsons Dis"},{"key":"2942_CR15","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.neuroimage.2005.03.012","volume":"26","author":"T Eckert","year":"2005","unstructured":"Eckert T, Barnes A, Dhawan V et al (2005) FDG PET in the differential diagnosis of parkinsonian disorders. NeuroImage 26:912\u2013921. https:\/\/doi.org\/10.1016\/j.neuroimage.2005.03.012","journal-title":"NeuroImage"},{"key":"2942_CR16","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1016\/j.neuron.2024.05.006","volume":"112","author":"H Endo","year":"2024","unstructured":"Endo H, Ono M, Takado Y et al (2024) Imaging \u03b1-synuclein pathologies in animal models and patients with Parkinson\u2019s and related diseases. Neuron 112:2540\u20132557e8. https:\/\/doi.org\/10.1016\/j.neuron.2024.05.006","journal-title":"Neuron"},{"key":"2942_CR17","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1002\/mds.28228","volume":"35","author":"M Filippi","year":"2020","unstructured":"Filippi M, Canu E, Donzuso G et al (2020) Tracking cortical changes throughout cognitive decline in Parkinson\u2019s disease. Mov Disord 35:1987\u20131998. https:\/\/doi.org\/10.1002\/mds.28228","journal-title":"Mov Disord"},{"key":"2942_CR18","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/mds.26349","volume":"30","author":"A Gesqui\u00e8re-Dando","year":"2015","unstructured":"Gesqui\u00e8re-Dando A, Guedj E, Loundou A et al (2015) A preoperative metabolic marker of parkinsonian apathy following subthalamic nucleus stimulation. Mov Disord 30:1767\u20131776. https:\/\/doi.org\/10.1002\/mds.26349","journal-title":"Mov Disord"},{"key":"2942_CR19","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1212\/WNL.0b013e3181dc1a55","volume":"74","author":"S Gilman","year":"2010","unstructured":"Gilman S, Koeppe RA, Nan B et al (2010) Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes. Neurology 74:1416\u20131423. https:\/\/doi.org\/10.1212\/WNL.0b013e3181dc1a55","journal-title":"Neurology"},{"key":"2942_CR20","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1212\/WNL.0000000000003764","volume":"88","author":"JG Goldman","year":"2017","unstructured":"Goldman JG, Bledsoe IO, Merkitch D et al (2017) Corpus callosal atrophy and associations with cognitive impairment in Parkinson disease. Neurology 88:1265\u20131272. https:\/\/doi.org\/10.1212\/WNL.0000000000003764","journal-title":"Neurology"},{"key":"2942_CR21","doi-asserted-by":"publisher","first-page":"338","DOI":"10.7326\/0003-4819-133-5-200009050-00009","volume":"133","author":"DS Goldstein","year":"2000","unstructured":"Goldstein DS, Holmes C, Li ST et al (2000) Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med 133:338\u2013347. https:\/\/doi.org\/10.7326\/0003-4819-133-5-200009050-00009","journal-title":"Ann Intern Med"},{"key":"2942_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1212\/WNL.0b013e31827b1a07","volume":"80","author":"SN Gomperts","year":"2013","unstructured":"Gomperts SN, Locascio JJ, Rentz D et al (2013) Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 80:85\u201391. https:\/\/doi.org\/10.1212\/WNL.0b013e31827b1a07","journal-title":"Neurology"},{"key":"2942_CR23","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1093\/brain\/awu159","volume":"137","author":"R Gonz\u00e1lez-Redondo","year":"2014","unstructured":"Gonz\u00e1lez-Redondo R, Garc\u00eda-Garc\u00eda D, Clavero P et al (2014) Grey matter hypometabolism and atrophy in Parkinson\u2019s disease with cognitive impairment: a two-step process. Brain 137:2356\u20132367. https:\/\/doi.org\/10.1093\/brain\/awu159","journal-title":"Brain"},{"key":"2942_CR24","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1002\/hbm.24884","volume":"41","author":"M Gorges","year":"2020","unstructured":"Gorges M, Kunz MS, M\u00fcller H-P et al (2020) Longitudinal brain atrophy distribution in advanced Parkinson\u2019s disease: what makes the difference in cognitive status converters? Hum Brain Mapp 41:1416\u20131434. https:\/\/doi.org\/10.1002\/hbm.24884","journal-title":"Hum Brain Mapp"},{"key":"2942_CR25","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00702-017-1717-8","volume":"124","author":"B Heim","year":"2017","unstructured":"Heim B, Krismer F, Marzi RD, Seppi K (2017) Magnetic resonance imaging for the diagnosis of Parkinson\u2019s disease. J Neural Transm 124:915\u2013964. https:\/\/doi.org\/10.1007\/s00702-017-1717-8","journal-title":"J Neural Transm"},{"key":"2942_CR26","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.2967\/jnumed.115.159822","volume":"56","author":"S Hellwig","year":"2015","unstructured":"Hellwig S, Frings L, Amtage F et al (2015) 18F-FDG PET is an early predictor of overall survival in suspected atypical parkinsonism. J Nucl Med 56:1541\u20131546. https:\/\/doi.org\/10.2967\/jnumed.115.159822","journal-title":"J Nucl Med"},{"key":"2942_CR27","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/mds.21956","volume":"23","author":"MA Hely","year":"2008","unstructured":"Hely MA, Reid WGJ, Adena MA et al (2008) The Sydney multicenter study of Parkinson\u2019s disease: the inevitability of dementia at 20 years. Mov Disord 23:837\u2013844. https:\/\/doi.org\/10.1002\/mds.21956","journal-title":"Mov Disord"},{"key":"2942_CR28","doi-asserted-by":"publisher","first-page":"103607","DOI":"10.1016\/j.nicl.2024.103607","volume":"42","author":"MG Hermann","year":"2024","unstructured":"Hermann MG, Schr\u00f6ter N, Rau A et al (2024) The connection of motor improvement after deep brain stimulation in Parkinson\u2019s disease and microstructural integrity of the substantia Nigra and subthalamic nucleus. Neuroimage Clin 42:103607. https:\/\/doi.org\/10.1016\/j.nicl.2024.103607","journal-title":"Neuroimage Clin"},{"key":"2942_CR29","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1007\/s00259-021-05325-z","volume":"48","author":"X Hu","year":"2021","unstructured":"Hu X, Sun X, Hu F et al (2021) Multivariate radiomics models based on 18F-FDG hybrid PET\/MRI for distinguishing between Parkinson\u2019s disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 48:3469\u20133481. https:\/\/doi.org\/10.1007\/s00259-021-05325-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2942_CR30","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2967\/jnumed.119.229443","volume":"61","author":"P Jain","year":"2020","unstructured":"Jain P, Chaney AM, Carlson ML et al (2020) Neuroinflammation PET imaging: current opinion and future directions. J Nucl Med 61:1107\u20131112. https:\/\/doi.org\/10.2967\/jnumed.119.229443","journal-title":"J Nucl Med"},{"key":"2942_CR31","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.neurom.2022.01.013","volume":"26","author":"H Jergas","year":"2023","unstructured":"Jergas H, Petry-Schmelzer JN, Dembek TA et al (2023) Brain morphometry associated with response to Levodopa and deep brain stimulation in Parkinson disease. Neuromodulation 26:340\u2013347. https:\/\/doi.org\/10.1016\/j.neurom.2022.01.013","journal-title":"Neuromodulation"},{"key":"2942_CR32","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s00702-023-02733-3","volume":"131","author":"WH Jost","year":"2024","unstructured":"Jost WH (2024) Advanced is advanced is advanced is advanced. J Neural Transm 131:1275\u20131276. https:\/\/doi.org\/10.1007\/s00702-023-02733-3","journal-title":"J Neural Transm"},{"key":"2942_CR33","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1159\/000314573","volume":"7","author":"WH Jost","year":"2010","unstructured":"Jost WH, Del Tredici K, Landvogt C, Braune S (2010) Importance of 123I-metaiodobenzylguanidine scintigraphy\/single photon emission computed tomography for diagnosis and differential diagnostics of Parkinson syndromes. Neurodegener Dis 7:341\u2013347. https:\/\/doi.org\/10.1159\/000314573","journal-title":"Neurodegener Dis"},{"key":"2942_CR34","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s00415-011-6187-6","volume":"259","author":"S Kato","year":"2012","unstructured":"Kato S, Watanabe H, Senda J et al (2012) Widespread cortical and subcortical brain atrophy in Parkinson\u2019s disease with excessive daytime sleepiness. J Neurol 259:318\u2013326. https:\/\/doi.org\/10.1007\/s00415-011-6187-6","journal-title":"J Neurol"},{"key":"2942_CR35","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1212\/WNL.0b013e3181d55f61","volume":"74","author":"JC Klein","year":"2010","unstructured":"Klein JC, Eggers C, Kalbe E et al (2010) Neurotransmitter changes in dementia with lewy bodies and Parkinson disease dementia in vivo. Neurology 74:885\u2013892. https:\/\/doi.org\/10.1212\/WNL.0b013e3181d55f61","journal-title":"Neurology"},{"key":"2942_CR36","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/brain\/awad322","volume":"147","author":"A Kouli","year":"2024","unstructured":"Kouli A, Spindler LRB, Fryer TD et al (2024) Neuroinflammation is linked to dementia risk in Parkinson\u2019s disease. Brain 147:923\u2013935. https:\/\/doi.org\/10.1093\/brain\/awad322","journal-title":"Brain"},{"key":"2942_CR37","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1474-4422(20)30346-X","volume":"19","author":"WC Kreisl","year":"2020","unstructured":"Kreisl WC, Kim M-J, Coughlin JM et al (2020) PET imaging of neuroinflammation in neurological disorders. Lancet Neurol 19:940\u2013950. https:\/\/doi.org\/10.1016\/S1474-4422(20)30346-X","journal-title":"Lancet Neurol"},{"key":"2942_CR38","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/brain\/awad338","volume":"147","author":"C Laurencin","year":"2024","unstructured":"Laurencin C, Lancelot S, Brosse S et al (2024) Noradrenergic alterations in Parkinson\u2019s disease: a combined 11\u00a0C-yohimbine PET\/neuromelanin MRI study. Brain 147:1377\u20131388. https:\/\/doi.org\/10.1093\/brain\/awad338","journal-title":"Brain"},{"key":"2942_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s41824-024-00194-9","volume":"8","author":"IHK Leung","year":"2024","unstructured":"Leung IHK, Strudwick MW (2024) A systematic review of the challenges, emerging solutions and applications, and future directions of PET\/MRI in Parkinson\u2019s disease. EJNMMI Rep 8:3. https:\/\/doi.org\/10.1186\/s41824-024-00194-9","journal-title":"EJNMMI Rep"},{"key":"2942_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-024-00717-y","volume":"10","author":"PA Loehrer","year":"2024","unstructured":"Loehrer PA, Bopp MHA, Dafsari HS et al (2024a) Microstructure predicts non-motor outcomes following deep brain stimulation in Parkinson\u2019s disease. Npj Parkinsons Dis 10:1\u20139. https:\/\/doi.org\/10.1038\/s41531-024-00717-y","journal-title":"Npj Parkinsons Dis"},{"key":"2942_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-024-00695-1","volume":"10","author":"PA Loehrer","year":"2024","unstructured":"Loehrer PA, Schumacher W, Jost ST et al (2024b) No evidence for an association of voxel-based morphometry with short-term non-motor outcomes in deep brain stimulation for Parkinson\u2019s disease. Npj Parkinsons Dis 10:1\u20138. https:\/\/doi.org\/10.1038\/s41531-024-00695-1","journal-title":"Npj Parkinsons Dis"},{"key":"2942_CR42","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1212\/WNL.0000000000002286","volume":"86","author":"M L\u00f6hle","year":"2016","unstructured":"L\u00f6hle M, Mende J, Wolz M et al (2016) Putaminal dopamine turnover in de Novo Parkinson disease predicts later motor complications. Neurology 86:231\u2013240. https:\/\/doi.org\/10.1212\/WNL.0000000000002286","journal-title":"Neurology"},{"key":"2942_CR43","doi-asserted-by":"publisher","first-page":"4047392","DOI":"10.1155\/2017\/4047392","volume":"2017","author":"M-R Luquin","year":"2017","unstructured":"Luquin M-R, Kulisevsky J, Martinez-Martin P et al (2017) Consensus on the definition of advanced Parkinson\u2019s disease: A Neurologists-Based Delphi study (CEPA study). Parkinsons Dis 2017:4047392. https:\/\/doi.org\/10.1155\/2017\/4047392","journal-title":"Parkinsons Dis"},{"key":"2942_CR44","doi-asserted-by":"publisher","first-page":"e25253","DOI":"10.1002\/jnr.25253","volume":"102","author":"SL Martin","year":"2024","unstructured":"Martin SL, Uribe C, Strafella AP (2024) PET imaging of synaptic density in parkinsonian disorders. J Neurosci Res 102:e25253. https:\/\/doi.org\/10.1002\/jnr.25253","journal-title":"J Neurosci Res"},{"key":"2942_CR45","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.3390\/brainsci11121557","volume":"11","author":"JC Mart\u00ednez-Castrillo","year":"2021","unstructured":"Mart\u00ednez-Castrillo JC, Mart\u00ednez-Mart\u00edn P, Burgos \u00c1 et al (2021) Prevalence of advanced Parkinson\u2019s disease in patients treated in the hospitals of the Spanish National healthcare system: the PARADISE study. Brain Sci 11:1557. https:\/\/doi.org\/10.3390\/brainsci11121557","journal-title":"Brain Sci"},{"key":"2942_CR46","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00259-019-04488-0","volume":"47","author":"SP McCluskey","year":"2020","unstructured":"McCluskey SP, Plisson C, Rabiner EA, Howes O (2020) Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development. Eur J Nucl Med Mol Imaging 47:451\u2013489. https:\/\/doi.org\/10.1007\/s00259-019-04488-0","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2942_CR47","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/hbm.22282","volume":"35","author":"RAL Menke","year":"2014","unstructured":"Menke RAL, Szewczyk-Krolikowski K, Jbabdi S et al (2014) Comprehensive morphometry of subcortical grey matter structures in early-stage Parkinson\u2019s disease. Hum Brain Mapp 35:1681\u20131690. https:\/\/doi.org\/10.1002\/hbm.22282","journal-title":"Hum Brain Mapp"},{"key":"2942_CR48","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.2967\/jnumed.116.186403","volume":"58","author":"PT Meyer","year":"2017","unstructured":"Meyer PT, Frings L, R\u00fccker G, Hellwig S (2017) 18F-FDG PET in parkinsonism: differential diagnosis and evaluation of cognitive impairment. J Nucl Med 58:1888\u20131898. https:\/\/doi.org\/10.2967\/jnumed.116.186403","journal-title":"J Nucl Med"},{"key":"2942_CR49","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1001\/jamaneurol.2021.1312","volume":"78","author":"T Mitchell","year":"2021","unstructured":"Mitchell T, Leh\u00e9ricy S, Chiu SY et al (2021) Emerging neuroimaging biomarkers across disease stage in Parkinson disease. JAMA Neurol 78:1262\u20131272. https:\/\/doi.org\/10.1001\/jamaneurol.2021.1312","journal-title":"JAMA Neurol"},{"key":"2942_CR50","doi-asserted-by":"publisher","first-page":"103022","DOI":"10.1016\/j.nicl.2022.103022","volume":"34","author":"T Mitchell","year":"2022","unstructured":"Mitchell T, Wilkes BJ, Archer DB et al (2022) Advanced diffusion imaging to track progression in Parkinson\u2019s disease, multiple system atrophy, and progressive supranuclear palsy. Neuroimage Clin 34:103022. https:\/\/doi.org\/10.1016\/j.nicl.2022.103022","journal-title":"Neuroimage Clin"},{"key":"2942_CR51","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.parkreldis.2021.07.021","volume":"90","author":"T Ogawa","year":"2021","unstructured":"Ogawa T, Hatano T, Kamagata K et al (2021) White matter alterations in Parkinson\u2019s disease with levodopa-induced dyskinesia. Parkinsonism Relat Disord 90:8\u201314. https:\/\/doi.org\/10.1016\/j.parkreldis.2021.07.021","journal-title":"Parkinsonism Relat Disord"},{"key":"2942_CR52","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/ene.14009","volume":"26","author":"A Okuzumi","year":"2019","unstructured":"Okuzumi A, Hatano T, Kamagata K et al (2019) Neuromelanin or DaT-SPECT: which is the better marker for discriminating advanced Parkinson\u2019s disease? Eur J Neurol 26:1408\u20131416. https:\/\/doi.org\/10.1111\/ene.14009","journal-title":"Eur J Neurol"},{"key":"2942_CR53","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/ana.24859","volume":"81","author":"G Pagano","year":"2017","unstructured":"Pagano G, Niccolini F, Fusar-Poli P, Politis M (2017) Serotonin transporter in Parkinson\u2019s disease: A meta-analysis of positron emission tomography studies. Ann Neurol 81:171\u2013180. https:\/\/doi.org\/10.1002\/ana.24859","journal-title":"Ann Neurol"},{"key":"2942_CR54","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/mds.26191","volume":"30","author":"M Petrou","year":"2015","unstructured":"Petrou M, Dwamena BA, Foerster BR et al (2015) Amyloid deposition in Parkinson\u2019s disease and cognitive impairment: a systematic review. Mov Disord 30:928\u2013935. https:\/\/doi.org\/10.1002\/mds.26191","journal-title":"Mov Disord"},{"key":"2942_CR55","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1002\/ana.410420508","volume":"42","author":"P Piccini","year":"1997","unstructured":"Piccini P, Weeks RA, Brooks DJ (1997) Alterations in opioid receptor binding in Parkinson\u2019s disease patients with levodopa-induced dyskinesias. Ann Neurol 42:720\u2013726. https:\/\/doi.org\/10.1002\/ana.410420508","journal-title":"Ann Neurol"},{"key":"2942_CR56","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1172\/JCI71640","volume":"124","author":"M Politis","year":"2014","unstructured":"Politis M, Wu K, Loane C et al (2014) Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson\u2019s disease patients. J Clin Invest 124:1340\u20131349. https:\/\/doi.org\/10.1172\/JCI71640","journal-title":"J Clin Invest"},{"key":"2942_CR57","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ibneur.2025.01.003","volume":"18","author":"W Qi","year":"2025","unstructured":"Qi W, Niu X, Zhan X et al (2025) Multimodal magnetic resonance imaging studies on non-motor symptoms of Parkinson\u2019s disease. IBRO Neurosci Rep 18:180\u2013190. https:\/\/doi.org\/10.1016\/j.ibneur.2025.01.003","journal-title":"IBRO Neurosci Rep"},{"key":"2942_CR58","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00062-020-00993-0","volume":"31","author":"A Rau","year":"2021","unstructured":"Rau A, Kim S, Yang S et al (2021) SVM-Based normal pressure hydrocephalus detection. Clin Neuroradiol 31:1029\u20131035. https:\/\/doi.org\/10.1007\/s00062-020-00993-0","journal-title":"Clin Neuroradiol"},{"key":"2942_CR59","doi-asserted-by":"publisher","unstructured":"Rau A, Philipsen L, Frings L et al (2025) Hippocampus and basal forebrain degeneration differentially impact cognition in lewy body spectrum disorders. https:\/\/doi.org\/10.1093\/brain\/awaf070. Brain awaf070","DOI":"10.1093\/brain\/awaf070"},{"key":"2942_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-024-00734-x","volume":"10","author":"T Rosinvil","year":"2024","unstructured":"Rosinvil T, Postuma RB, Rahayel S et al (2024) Clinical symptoms and neuroanatomical substrates of daytime sleepiness in Parkinson\u2019s disease. Npj Parkinsons Dis 10:1\u201311. https:\/\/doi.org\/10.1038\/s41531-024-00734-x","journal-title":"Npj Parkinsons Dis"},{"key":"2942_CR61","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.parkreldis.2019.10.002","volume":"73","author":"SG Ryman","year":"2020","unstructured":"Ryman SG, Poston KL (2020) MRI biomarkers of motor and non-motor symptoms in Parkinson\u2019s disease. Parkinsonism Relat Disord 73:85\u201393. https:\/\/doi.org\/10.1016\/j.parkreldis.2019.10.002","journal-title":"Parkinsonism Relat Disord"},{"key":"2942_CR62","doi-asserted-by":"publisher","first-page":"572976","DOI":"10.3389\/fneur.2020.572976","volume":"11","author":"U Saeed","year":"2020","unstructured":"Saeed U, Lang AE, Masellis M (2020) Neuroimaging advances in Parkinson\u2019s disease and atypical parkinsonian syndromes. Front Neurol 11:572976. https:\/\/doi.org\/10.3389\/fneur.2020.572976","journal-title":"Front Neurol"},{"key":"2942_CR63","doi-asserted-by":"publisher","first-page":"100037","DOI":"10.1016\/j.dscb.2022.100037","volume":"6","author":"E Samson","year":"2022","unstructured":"Samson E, Noseworthy MD (2022) A review of diagnostic imaging approaches to assessing Parkinson\u2019s disease. Brain Disorders 6:100037. https:\/\/doi.org\/10.1016\/j.dscb.2022.100037","journal-title":"Brain Disorders"},{"key":"2942_CR64","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1474-4422(18)30169-8","volume":"17","author":"KA Schindlbeck","year":"2018","unstructured":"Schindlbeck KA, Eidelberg D (2018) Network imaging biomarkers: insights and clinical applications in Parkinson\u2019s disease. Lancet Neurol 17:629\u2013640. https:\/\/doi.org\/10.1016\/S1474-4422(18)30169-8","journal-title":"Lancet Neurol"},{"key":"2942_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41531-022-00401-z","volume":"8","author":"N Schr\u00f6ter","year":"2022","unstructured":"Schr\u00f6ter N, Rijntjes M, Urbach H et al (2022) Disentangling nigral and putaminal contribution to motor impairment and Levodopa response in Parkinson\u2019s disease. Npj Parkinsons Dis 8:1\u20138. https:\/\/doi.org\/10.1038\/s41531-022-00401-z","journal-title":"Npj Parkinsons Dis"},{"key":"2942_CR66","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/mdc3.13792","volume":"10","author":"N Schr\u00f6ter","year":"2023","unstructured":"Schr\u00f6ter N, Bormann T, Rijntjes M et al (2023) Cognitive deficits in Parkinson\u2019s disease are associated with neuronal dysfunction and not white matter lesions. Mov Disorders Clin Pract 10:1066\u20131073. https:\/\/doi.org\/10.1002\/mdc3.13792","journal-title":"Mov Disorders Clin Pract"},{"key":"2942_CR65","doi-asserted-by":"publisher","DOI":"10.1007\/s00062-023-01377-w","author":"N Schr\u00f6ter","year":"2024","unstructured":"Schr\u00f6ter N, Arnold PG, Hosp JA et al (2024a) Complemental value of microstructural and macrostructural MRI in the discrimination of neurodegenerative Parkinson syndromes. Clin Neuroradiol. https:\/\/doi.org\/10.1007\/s00062-023-01377-w","journal-title":"Clin Neuroradiol"},{"key":"2942_CR68","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-024-02773-3","author":"N Schr\u00f6ter","year":"2024","unstructured":"Schr\u00f6ter N, Sajonz BEA, Jost WH et al (2024b) Advanced therapies in Parkinson\u2019s disease: an individualized approach to their indication. J Neural Transm. https:\/\/doi.org\/10.1007\/s00702-024-02773-3","journal-title":"J Neural Transm"},{"key":"2942_CR69","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1093\/brain\/awy072","volume":"141","author":"J Schulz","year":"2018","unstructured":"Schulz J, Pagano G, Fern\u00e1ndez Bonfante JA et al (2018) Nucleus basalis of meynert degeneration precedes and predicts cognitive impairment in Parkinson\u2019s disease. Brain 141:1501\u20131516. https:\/\/doi.org\/10.1093\/brain\/awy072","journal-title":"Brain"},{"key":"2942_CR70","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/mds.26369","volume":"31","author":"N Shah","year":"2016","unstructured":"Shah N, Frey KA, M\u00fcller MLTM et al (2016) Striatal and cortical \u03b2-Amyloidopathy and cognition in Parkinson\u2019s disease. Mov Disord 31:111\u2013117. https:\/\/doi.org\/10.1002\/mds.26369","journal-title":"Mov Disord"},{"key":"2942_CR71","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/s42003-021-02705-x","volume":"4","author":"S Shang","year":"2021","unstructured":"Shang S, Li D, Tian Y et al (2021) Hybrid PET-MRI for early detection of dopaminergic dysfunction and microstructural degradation involved in Parkinson\u2019s disease. Commun Biol 4:1162. https:\/\/doi.org\/10.1038\/s42003-021-02705-x","journal-title":"Commun Biol"},{"key":"2942_CR72","doi-asserted-by":"publisher","first-page":"6750","DOI":"10.1038\/s41467-023-42305-3","volume":"14","author":"R Smith","year":"2023","unstructured":"Smith R, Capotosti F, Schain M et al (2023) The \u03b1-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases. Nat Commun 14:6750. https:\/\/doi.org\/10.1038\/s41467-023-42305-3","journal-title":"Nat Commun"},{"key":"2942_CR73","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/mds.29320","volume":"38","author":"D Su","year":"2023","unstructured":"Su D, Gan Y, Zhang Z et al (2023) Multimodal imaging of substantia Nigra in Parkinson\u2019s disease with Levodopa-Induced dyskinesia. Mov Disord 38:616\u2013625. https:\/\/doi.org\/10.1002\/mds.29320","journal-title":"Mov Disord"},{"key":"2942_CR74","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1002\/mds.29273","volume":"38","author":"Y Tang","year":"2023","unstructured":"Tang Y, Li L, Hu T et al (2023) In vivo 18 F-Florzolotau Tau positron emission tomography imaging in Parkinson\u2019s disease dementia. Mov Disord 38:147\u2013152. https:\/\/doi.org\/10.1002\/mds.29273","journal-title":"Mov Disord"},{"key":"2942_CR75","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13195-018-0428-1","volume":"10","author":"M ten Kate","year":"2018","unstructured":"ten Kate M, Redolfi A, Peira E et al (2018) MRI predictors of amyloid pathology: results from the EMIF-AD multimodal biomarker discovery study. Alz Res Therapy 10:100. https:\/\/doi.org\/10.1186\/s13195-018-0428-1","journal-title":"Alz Res Therapy"},{"key":"2942_CR76","first-page":"1775","volume":"46","author":"DN Tipre","year":"2005","unstructured":"Tipre DN, Goldstein DS (2005) Cardiac and extracardiac sympathetic denervation in Parkinson\u2019s disease with orthostatic hypotension and in pure autonomic failure. J Nucl Med 46:1775\u20131781","journal-title":"J Nucl Med"},{"key":"2942_CR77","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1148\/radiol.2020191235","volume":"296","author":"P Vitali","year":"2020","unstructured":"Vitali P, Pan MI, Palesi F et al (2020) Substantia Nigra volumetry with 3-T MRI in de Novo and advanced Parkinson disease. Radiology 296:401\u2013410. https:\/\/doi.org\/10.1148\/radiol.2020191235","journal-title":"Radiology"},{"key":"2942_CR79","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1007\/s10072-019-04014-y","volume":"40","author":"X Wang","year":"2019","unstructured":"Wang X, Zhang Y, Zhu C et al (2019) The diagnostic value of SNpc using NM-MRI in Parkinson\u2019s disease: meta-analysis. Neurol Sci 40:2479\u20132489. https:\/\/doi.org\/10.1007\/s10072-019-04014-y","journal-title":"Neurol Sci"},{"key":"2942_CR78","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3389\/fnins.2020.00029","volume":"14","author":"X Wang","year":"2020","unstructured":"Wang X, Wang M, Yuan Y et al (2020) Altered amplitude of Low-Frequency fluctuations and functional connectivity in excessive daytime sleepiness in Parkinson disease. Front Neurosci 14:29. https:\/\/doi.org\/10.3389\/fnins.2020.00029","journal-title":"Front Neurosci"},{"key":"2942_CR80","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.parkreldis.2016.01.012","volume":"24","author":"M-C Wen","year":"2016","unstructured":"Wen M-C, Ng SYE, Heng HSE et al (2016) Neural substrates of excessive daytime sleepiness in early drug Na\u00efve Parkinson\u2019s disease: A resting state functional MRI study. Parkinsonism Relat Disord 24:63\u201368. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.01.012","journal-title":"Parkinsonism Relat Disord"},{"key":"2942_CR81","doi-asserted-by":"publisher","first-page":"326","DOI":"10.2967\/jnumed.116.176891","volume":"58","author":"KK Wong","year":"2017","unstructured":"Wong KK, Raffel DM, Bohnen NI et al (2017) 2-Year natural decline of cardiac sympathetic innervation in idiopathic Parkinson disease studied with 11\u00a0C-Hydroxyephedrine PET. J Nucl Med 58:326\u2013331. https:\/\/doi.org\/10.2967\/jnumed.116.176891","journal-title":"J Nucl Med"},{"key":"2942_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-024-00787-9","volume":"20","author":"J Xiang","year":"2025","unstructured":"Xiang J, Zhang Z, Wu S, Ye K (2025) Positron emission tomography tracers for synucleinopathies. Mol Neurodegeneration 20:1. https:\/\/doi.org\/10.1186\/s13024-024-00787-9","journal-title":"Mol Neurodegeneration"},{"key":"2942_CR83","doi-asserted-by":"publisher","first-page":"22065","DOI":"10.1038\/s41598-020-79138-9","volume":"10","author":"Y Yim","year":"2020","unstructured":"Yim Y, Kim SJ, Jung SC et al (2020) Pretreatment brain volumes can affect the effectiveness of deep brain stimulation in Parkinson\u2019s disease patients. Sci Rep 10:22065. https:\/\/doi.org\/10.1038\/s41598-020-79138-9","journal-title":"Sci Rep"},{"key":"2942_CR84","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s10072-019-04206-6","volume":"41","author":"S-W Yoo","year":"2020","unstructured":"Yoo S-W, Oh Y-S, Ryu D-W et al (2020) Low thalamic monoamine transporter availability is related to excessive daytime sleepiness in early Parkinson\u2019s disease. Neurol Sci 41:1081\u20131087. https:\/\/doi.org\/10.1007\/s10072-019-04206-6","journal-title":"Neurol Sci"},{"key":"2942_CR85","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jns.2018.02.032","volume":"387","author":"T Yousaf","year":"2018","unstructured":"Yousaf T, Pagano G, Niccolini F, Politis M (2018) Excessive daytime sleepiness May be associated with caudate denervation in Parkinson disease. J Neurol Sci 387:220\u2013227. https:\/\/doi.org\/10.1016\/j.jns.2018.02.032","journal-title":"J Neurol Sci"},{"key":"2942_CR86","doi-asserted-by":"publisher","first-page":"1145939","DOI":"10.3389\/fneur.2023.1145939","volume":"14","author":"J Zhang","year":"2023","unstructured":"Zhang J, Jin J, Su D et al (2023) Tau-PET imaging in Parkinson\u2019s disease: a systematic review and meta-analysis. Front Neurol 14:1145939. https:\/\/doi.org\/10.3389\/fneur.2023.1145939","journal-title":"Front Neurol"},{"key":"2942_CR87","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00062-022-01190-x","volume":"33","author":"JH Zheng","year":"2023","unstructured":"Zheng JH, Ma JJ, Sun WH et al (2023) Excessive daytime sleepiness in Parkinson\u2019s disease is related to functional abnormalities in the left angular gyrus. Clin Neuroradiol 33:121\u2013127. https:\/\/doi.org\/10.1007\/s00062-022-01190-x","journal-title":"Clin Neuroradiol"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-02942-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-025-02942-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-02942-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T14:44:25Z","timestamp":1763563465000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-025-02942-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":87,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2942"],"URL":"https:\/\/doi.org\/10.1007\/s00702-025-02942-y","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"1 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflicts of interest in regard to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}